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Abstract
Based on the partial efficacy of the HIV/AIDS Thai trial (RV144) with a canarypox vector prime and protein boost, attenuated
poxvirus recombinants expressing HIV-1 antigens are increasingly sought as vaccine candidates against HIV/AIDS. Here we
describe using systems analysis the biological and immunological characteristics of the attenuated vaccinia virus Ankara
strain expressing the HIV-1 antigens Env/Gag-Pol-Nef of HIV-1 of clade C (referred as MVA-C). MVA-C infection of human
monocyte derived dendritic cells (moDCs) induced the expression of HIV-1 antigens at high levels from 2 to 8 hpi and
triggered moDCs maturation as revealed by enhanced expression of HLA-DR, CD86, CD40, HLA-A2, and CD80 molecules.
Infection ex vivo of purified mDC and pDC with MVA-C induced the expression of immunoregulatory pathways associated
with antiviral responses, antigen presentation, T cell and B cell responses. Similarly, human whole blood or primary
macrophages infected with MVA-C express high levels of proinflammatory cytokines and chemokines involved with T cell
activation. The vector MVA-C has the ability to cross-present antigens to HIV-specific CD8 T cells in vitro and to increase CD8
T cell proliferation in a dose-dependent manner. The immunogenic profiling in mice after DNA-C prime/MVA-C boost
combination revealed activation of HIV-1-specific CD4 and CD8 T cell memory responses that are polyfunctional and with
effector memory phenotype. Env-specific IgG binding antibodies were also produced in animals receiving DNA-C prime/
MVA-C boost. Our systems analysis of profiling immune response to MVA-C infection highlights the potential benefit of
MVA-C as vaccine candidate against HIV/AIDS for clade C, the prevalent subtype virus in the most affected areas of the
world.
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Introduction
While a vaccine against HIV/AIDS has remained elusive since
the pandemic first appeared, the recent findings from the phase III
Thailand clinical trial with the combination of a canary poxvirus
vector (ALVAC) and purified protein gp120 (RV144) giving
31.2% protection against HIV infection [1], while it was not
sustain, it open the possibility of improving HIV/AIDS efficacy
through modification of some of the vaccine components similar as
those used in the Thai trial. Potential vaccine improvements
include the use of other attenuated poxvirus vectors, like MVA
and NYVAC [2,3], genetic modification of the poxvirus vectors
through deletion of viral immunomodulatory genes [4,5,6,7,8] and
prime/boost combination with heterologous vectors with or
without adjuvants and co-stimulatory molecules [9,10,11]. A
number of phase I/II clinical trials have been performed or are
on-going with poxvirus vectors administered alone or in prime/
boost combination (http://www.iavi.org). The clinical findings
obtained thus far revealed that attenuated poxvirus vectors when
used alone induced lower immune responses that when combined
in prime/boost protocols with heterologous vectors [9,12]. As yet
it remains unclear which of the poxvirus vectors is optimal in
triggering immune responses. A deep understanding on the
immune characteristics of these vectors is needed, as each vector
might impact the immune system differently. This has been
highlighted for NYVAC and MVA vectors [13,14], as these
vectors have differential deletions of viral immunomodulatory
genes. One of the attenuated poxvirus vectors that is going to enter
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for subtype C, i.e, Env gp120 as a cell released product and the
fusion polyprotein Gag-Pol-Nef as intracellular component
(referred as MVA-C). As yet, there is limited information on the
characteristics of this vector. Herein, we use systems biology to
characterize the global immune response and provide in-depth
characterization of the biological and immune features of MVA-C
in human cells and in animals. Our results showed that MVA-C is
an excellent immunogen, as it expresses at high levels the HIV-1
antigens in human moDCs, triggers DC maturation, activates
wide expression of immunostimulatory molecules, induces cross-
presentation and CD8
+ T cell proliferation and, in vaccinated
mice by prime/boost protocols, activates HIV-1-specific CD4 and
CD8 memory responses that are polyfunctional and with effector
memory phenotype (TEM). These observations point MVA-C
vector as promising HIV/AIDS vaccine candidate.
Results
Expression of HIV antigens in DCs infected with MVA-C
We have previously described that MVA-C infection of human
HeLa cells in culture induces the expression of gp120 and of the
polyprotein Gag-Pol-Nef as determined by Western blot [15]. The
organization of the HIV genes in the TK locus of the MVA
genome is shown as scheme in Fig. 1A. To define the gene
expression capacity of MVA-C in human monocyte-derived
dendritic cells (moDCs), we evaluated the expression levels of
HIV Gag by flow cytometry. As shown in Fig. 1B, Gag expression
increases with time of infection. Of relevance, 60% of the cells
expressed Gag by 2 h post infection and the levels were reduced by
24 h, possibly due to apoptosis induction at late times post
infection [16]. The high levels of HIV antigen expression in
moDCs early in infection is due to the nature of the promoter, as
both gp120 and Gag-Pol-Nef genes expression is driven by a
synthetic early/late virus promoter. These findings showed the
high capacity of MVA-C to express HIV antigens in human DCs,
which are critical cells in the activation of innate immune
responses.
Transcriptional analyses of mDC and pDC infected with
MVA-C revealed the global induction of innate and
adaptive immunoregulatory pathways
In order to characterize the global response elicited by MVA-C
in ex vivo purified human myeloid (mDCs) and plasmacytoid
(pDCs) dendritic cells, we determined the transcriptional profiles
using gene array analysis. We compared the transcriptional
profiles of MVA-C infected mDCs and pDCs (n=6) to mock
infected cells (n=14). Unsupervised clustering using multidimen-
sional scaling (MDS) revealed, as expected, distinct transcriptional
profiles between mDCs and pDCs either in the mock- or MVA-C-
infected subsets (Fig. S1). This confirms our previous reports
showing differences in the transcriptional signatures of mDCs and
pDCs in response to viral infection [7]. We then examined
separately the gene expression of mDC and pDC in response to
MVA-C infection. We show that infection of MVA-C significantly
induces the expression of more than 5500 genes in mDCs and
4500 genes in pDCs when compared to mock infection (adjusted
p-value of ,0.05 false discover rate FDR). Complete lists of all
significant genes that are induced following MVA-C infection of
mDCs and pDCs are presented in tables S1 and S2, respectively.
Further analysis of the top 30 genes induced by MVA-C in mDCs
revealed the increased expression of interferon (IFNB1) and IFN-
induced genes (IFIT2, IFIT3, OASL, GBP4), inflammatory
molecules (CXCL9, CXCL10, and TNF-a) and antiviral genes
such as ZC3HAV1 that has been shown to have a potent anti-
retroviral activity [17] (Fig. 2A). Similarly, in pDCs the top 30
genes showed the increased expression of IFN genes (IFNB1,
IFNA2, IFNA16), IFN-induced genes (IFIT3) and anti-retroviral
genes such as TRIM5 (Fig. 2B). We then analysed significant genes
that are associated with specific immune function in mDCs and
pDCs infected with MVA-C. Fig. 3A shows that MVA-C induced
the expression of genes that are associated with DC maturation
and activation including CD40, CD80 and cytokines that are
critical for T cell and B cell responses including IL-6, IL12, and
IL-28. Furthermore, we examined genes that are critical for
antiviral activity. Fig. 3B shows significant induction of more than
15 genes that are associated with IFN response in mDCs. Similar
induction was also observed in pDCs (Fig. 3C). In addition,
infection with MVA-C induced the expression of genes associated
with inflammatory response such as CXCL9 and CXCL10 in
mDC and pDC (Fig. 3D and Fig. 3E, respectively).
Overall, these results demonstrate that MVA-C induces the
expression of large number of biologically significant genes in
mDC and pDC subsets. These induced genes play an important
role in regulating adaptive immune response as well as in exerting
antiviral effect.
While gene transcription does not provide functional informa-
tion, however it gives an indication of how genes can be placed
into specific cellular pathways. Thus, we investigated signaling
pathways induced upon infection of mDC and pDC subsets with
MVA-C. We observed the activation of multiple innate and
adaptive immunoregulatory pathways in mDC and pDC com-
partments. Fig. 4A depicts a list of top signaling pathways that are
elicited in mDC following infection with MVA-C. For example,
MVA-C infection induces IFN signaling, antiviral and IRF
pathways. Selective genes were depicted in each of these pathways
including IFIT3, IFIT1, IFITM for IFN signaling; TRAF5,
APAF1, IRF7 for antiviral, and ADAR, IRF7, IFIH1 and DDX58
for IRF pathways (Fig. 3). We also observed the induction of
pathways associated with the activation of the adaptive immune
response including CD28 signaling, IL-6 signaling, and antigen
presentation. Similar innate and adaptive pathways were also
induced in pDC infected with MVA-C (Fig. 4B).
Maturation of DCs after infection with MVA-C
Since previous studies have shown that infection of human DCs
with the non-recombinant MVA leads to an increase in
upregulation of CD86 and HLA-DR molecules [18,19] and in
order to confirm our gene expression data, we next determined the
effects of MVA-C on moDC maturation through the analyses of
several cellular surface markers. As shown in Fig. 5, expression
levels of HLA-DR, CD86, CD40, HLA-A2 and CD80 were all
increased in MVA-C-infected cells. These results demonstrate that
MVA-C is able to induce enhanced phenotypic DC maturation in
the absence of other stimuli.
Enhanced cytokine and chemokine production after
infection with MVA-C
To further characterize the effects of MVA-C infection on
human cells, we next defined the expression levels of some selected
cytokines, chemokines, signaling and accessory molecules in
primary human macrophages. We first examined by RT-PCR
the mRNA levels of these molecules in cells infected with MVA-C
(5 pfu/cell) for 3 h. As shown in Fig. 6A, mRNA levels of genes
encoding for chemokines (CXCL1 and CXCL5), cytokines (IL-10,
IL-15 and IL-32), pattern recognition receptors (TLR1) and innate
signaling molecules like IRAK3 and TRAF6, were all increased
after MVA-C infection in comparison with MVA-WT-infected
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ILT5 and ETS2 mRNAs, suggesting an increased capacity to
induce T cell signaling. Then, cell-free supernatants from primary
human macrophages infected for 24 h with parental or recombi-
nant MVA-C viruses (1 and 5 pfu/cell) were used to quantify by
ELISA cytokine and chemokine production. As shown in Fig. 6B,
there was an increase in the levels of type I IFNs (IFNa and IFNb),
chemokines (IP-10, MIP-1a and RANTES) and cytokines (IL-8
and IL-1b) secreted in the MVA-C-infected cells at the two
different multiplicities compared with the control. Similar
increases of chemokines and cytokines were obtained after
MVA-C infection (24 h with 1 and 5 pfu/cell) of whole human
blood (not shown).
MVA-C infection induces cross-presentation to CD8 T
cells and T cell proliferation
We have previously described an assay to determine the ability
of moDCs to cross-present antigens from apoptotic infected HeLa
cells [7]. Human moDCs were incubated with apoptotic infected
HeLa cells before an HIV-specifc CD8 T cell clone was added
and, after overnight incubation, cells were harvested and among
Figure 1. MVA-C induces the expression of HIV gag antigen early after infection of human DCs. A) Schematic diagram of MVA-C
genome. B) Histograms show anti-Gag KC57 staining of infected moDCs. Cells were infected at 1 pfu/cell and at different times after infection cells
were harvested and stained for Gag expression by ICS as described under Materials and Methods. Percentage of Gag-expressing cells is indicated.
doi:10.1371/journal.pone.0035485.g001
HIV/AIDS Vaccine Candidate Based on MVA-C
PLoS ONE | www.plosone.org 3 April 2012 | Volume 7 | Issue 4 | e35485HIV/AIDS Vaccine Candidate Based on MVA-C
PLoS ONE | www.plosone.org 4 April 2012 | Volume 7 | Issue 4 | e35485the lymphocyte population, CD8 T cells were gated and analyzed
for IFN-c, TNF-a, IL-2 and MIP-1b production. The results
shown in Fig. 7A with percentages of CD8 T cells producing any
cytokine revealed cross-presentation to HIV-specific CD8 T cell
clone triggered by MVA-C infection, in contrast with the control.
This cross-presentation was virus multiplicity-dependent.
Furthermore, we also measured the HIV-specific proliferative
capacity of CFSE-labeled human PBMCs from an HIV-infected
long-term non-progressor upon infection with MVA-C or MVA-
WT, as described under Materials and Methods. Fig. 7B
represents CD8 T cell proliferation as determined by CFSE
dilution measured at day 6 after stimulation with MVA-C at
different virus multiplicities. High proliferation up to 20% was
observed after infection with 10
6 pfu of MVA-C. Together, the
data of Fig. 7 revealed that both cross-presentation and
proliferation of CD8 T cells are induced by MVA-C infection of
human immune cells.
MVA-C infection activates memory HIV-1-specific T cell
immune responses
Since triggering of both humoral and cellular arms of the
immune system might be needed for HIV prevention in humans
[20] and activation of T effector memory cell (TEM) response has
been associated with protection in NHP model [21,22], we next
characterized the ability of MVA-C to activate HIV-1-specific
immune responses in mice using a DNA prime/Pox boost
approach. Thus, Balb/c mice were inoculated by intramuscular
route (i.m.) with two plasmid DNA vectors expressing gp120 and
GPN of clade C or with sham DNA and boosted two weeks later
by intraperioneal route (i.p.) with MVA-C or parental MVA-WT.
Vaccine-induced T cell immune responses were evaluated at 53
days after the booster by polychromatic ICS assay after the
stimulation of splenocytes with a panel of 464 peptides (15 mers
overlapping by 11 amino acids) grouped in three pools: Env (112
peptides), Gag (121 peptides) and GPN (231 peptides). The
peptides encompassed the Env, Gag, Pol, and Nef proteins of
HIV-1 and were designed based on the sequence of the
immunogens expressed by MVA-C. As shown in Fig. 8A, the
magnitude of the HIV-1-specific CD4
+ and CD8
+ T cell
responses, determined as the sum of the individual responses
obtained for Env, Gag and GPN peptide pools, was significantly
higher in mice that received DNA-C prime/MVA-C boost than
that obtained in the control group DNA-w/MVA-WT (p,0.05).
The CD4
+ T cell responses were mainly directed against the Env
pool whereas the CD8
+ T cell responses were higher in magnitude,
and broader, triggered by both Env and GPN pools. On the basis
of the analysis of IL-2, TNF-a and IFN-c secretion, seven distinct
HIV-1-specific CD4
+ and CD8
+ T cell populations were identified
(Fig. 8B). Vaccine-induced CD4
+ and CD8
+ T cell responses were
polyfunctional, with more than 40% of antigen-specific T cells
exhibiting two or three functions. We also determined the
phenotype of the memory responses by measuring the expression
of CD62L and CD44 in the HIV-1-specific T cells. The effector
memory T cells (TEM) have a CD44
highCD62L
2 phenotype
whereas the central memory T cells (TCM) are CD44
highCD62L
+.
As shown in Fig. 8C, the HIV-1-specific CD4 and CD8 T cells
have a TEM phenotype, since more than 90% of the responding
cells were CD44
highCD62L
2. Similar findings were observed in
two independent experiments. Overall, the results revealed that
MVA-C positively impacts on the CD4
+ and CD8
+ T cell memory
phase of the immune response.
MVA-C induces humoral response to Env
Since induction of antibodies to gp120 has been associated with
a reduced risk of HIV infection in humans [23], we next evaluated
the antibody levels in serum from mice vaccinated in a DNA
prime/MVA boost protocol. An ELISA test with plates coated
with purified gp140 CN54 protein was used for antibody
specificity. As shown in Fig. 9A, anti-gp140 IgG binding
antibodies were detected only in animals that received DNA-C
prime/MVA-C boost, indicating that the released gp120
expressed during infection with MVA-C triggered specific
humoral responses. Almost all the anti-Env IgG binding antibodies
detected in MVA-C immunized animals were of IgG1 subtype
(Fig. 9B), indicating a Th2 response.
Discussion
At present, there is limited number of attenuated poxvirus
vectors expressing several HIV antigens considered as candidate
vaccines against HIV/AIDS that have entered phase I/II/III
clinical trials. The most advanced poxvirus vector with an
attenuated phenotype is the canarypox ALVAC expressing
gp120/Gag-Pro that has shown partial efficacy when combined
with the protein gp120 in the phase III clinical trial in Thailand
[1]. Other attenuated poxvirus vectors like NYVAC [9,24], MVA
[12,25,26,27,28,29,30] or Fowlpox [31] have shown different
immunogenic profiles when used alone or in combination with
other heterologous vectors in clinical trials, probably due the
nature of the vector, virus dose and HIV antigens being expressed.
We have previously shown that when poxvirus vectors MVA and
NYVAC expressing gp120/Gag-Pol-Nef are compared head-to-
head, there are clear differences in the induction of cellular genes
in response to virus infection that might lead to differences in the
activation of host cell immune responses [14,32]. Hence, the
immune response induced by each single poxvirus vector strain
must take into account those observations, as the immunological
properties might differ. In addition, replication competent
poxvirus vectors are also sought as vaccine candidates that might
be able to enhance the specific HIV immune responses, an aspect
that will be known in future clinical trials. From the point of view
of attenuated MVA vectors, many different vaccine candidates
expressing diverse HIV antigens have moved into clinical trials
with encouraging results [12,25,26,27,28,29,30]. We have recently
described the results of a phase I clinical trial with an MVA vector
expressing gp120 and Gag-Pol-Nef of HIV-1 from clade B (MVA-
B). We showed that MVA-B was safe, well tolerated and highly
immunogenic, inducing broad, polyfunctional, and long-lasting
CD4
+ and CD8
+ T cell responses to HIV-1 antigens, with
preference for effector memory T cells. Moreover, the vaccination
regimen also induced antibody responses to Env in the 95% of
volunteers [26,27].
As a new step to move forward with an MVA candidate for
clade C, the most prevalent in parts of Africa and Asia, here we
Figure 2. Genes induced by MVA-C in human mDCs and pDCs. A) Gene expression heatmap using the top 50 differentially expressed genes
resulting from comparing myeloid DCs infected with MVA-C (MDC_MVC) and mock-infected (MDC_Mock) groups. B) Gene expression heatmap using
the top 50 differentially expressed genes resulting from comparing plasmacytoid DCs infected with MVA-C (PDC_MVC) and mock-infected
(PDC_Mock) groups. Genes selected as differentially expressed based on the following criteria: adjusted p-value,0.05 and |FC|.1.3. The scale shows
the level of gene expression where Red and Blue correspond to up- and down-regulation respectively.
doi:10.1371/journal.pone.0035485.g002
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PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35485Figure 3. Significant genes associated with specific immune function in MVA-C-infected mDCs and pDCs. A) Gene expression heatmap
using selected set of immune related genes resulting from comparing myeloid DCs infected with MVA-C (MDC_MVC) and mock-infected
(MDC_Mock) groups. B) Gene expression heatmap using selected set of IFN-induced genes resulting from comparing myeloid DCs infected with
MVA-C (MDC_MVC) and mock-infected (MDC_Mock) groups. C) Gene expression heatmap using selected set of IFN signaling genes resulting from
comparing plasmacytoid DCs infected with MVA-C (PDC_MVC) and mock-infected (PDC_Mock) groups. D) Gene expression heatmap using selected
set of inflammation associated genes resulting from comparing myeloid DCs infected with MVA-C (MDC_MVC) and mock-infected (MDC_Mock)
groups. E) Gene expression heatmap using selected set of inflammation associated genes resulting from comparing plasmacytoid DCs infected with
MVA-C (PDC_MVC) and mock-infected (PDC_Mock) groups. The genes selected are differentially expressed (FC.1.3 and adjusted p-value,0.05). Red
and Blue correspond to up- and down-regulation respectively.
doi:10.1371/journal.pone.0035485.g003
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immune properties of the MVA-C vaccine vector that will enter
soon in phase I clinical trials. We showed that MVA-C is an
excellent immunogen, since it expresses at high levels the HIV
antigens in human moDCs, triggers DC maturation, activates the
expression of immunostimulatory molecules, induces cross-prim-
ing and CD8
+ T cell proliferation and, in mice vaccinated by
prime/boost protocol, induces antibodies and activates HIV-1-
specific CD4 and CD8 T cell memory responses that are
polyfunctional and of effector memory phenotype. In the context
of HIV vaccines, these biological and immune characteristics
might be relevant in the control of an HIV infection. In fact, it is
generally assumed that both humoral and cellular arms of the
immune system need to be activated in order to control HIV
infection, either through neutralizing antibodies, ADCC, or
cytotoxic T cells [20]. From the Thai trial and after examining
a large population of vaccinated individuals, it has been suggested
that production of antibodies, specifically directed to the V2 loop,
might be needed to control HIV infection, while high levels of IgA
are detrimental [23]. In the Thai trial the T cell responses were
low and, hence, it has not been as yet possible to conclude that this
arm of the immune system is dispensable or required. In fact, from
the NHP studies with a cytomegalovirus vector expressing SIV
antigens, it has been proposed that immune protection against a
virulent SIV challenge required activation of T cells of an effector
memory phenotype (TEM) [21,22]. In view of the fact that, as
shown here, MVA-C activates both in vitro and in vivo different
components of the immune system that might be needed for
protection against a pathogen, our immunogenicity study in mice
establish that MVA-C is an excellent HIV vaccine candidate with
production of both antibodies and T cell responses to HIV
antigens. It is significant the polyfunctional and broad nature of
the immune response triggered in mice, with preferential
activation in a DNA-C prime/MVA-C boost of memory T cell
responses of TEM phenotype. The vaccine-induced CD4
+ T cell
response was preferentially against Env whereas the CD8
+ T cell
response was directed against GPN and Env antigens. This is
particularly important when considering vaccination protocols, as
multiple challenges with the same immunogen might not be
required. Future animal studies should elucidate the optimal
combination of MVA-C with other vectors (i.e., Env protein,
heterologous viral vectors, adjuvants) that trigger enhanced B and
T cell responses. Overall, the results reported here points MVA-C
vector as promising HIV/AIDS vaccine candidate and support the
future phase I clinical trials with MVA-C.
Materials and Methods
Ethics statement
The animal studies were approved by the Ethical Committee of
Animal Experimentation (CEEA-CNB) of Centro Nacional de
Biotecnologia (CNB-CSIC) in accordance with national and
international guidelines and with the Royal Decree (RD 1201/
2005). Permit numbers: 152/07 and 080030.
Cells and viruses
Monocyte derived dendritic cells (moDCs) were obtained from
cryopreserved or freshly isolated peripheral blood mononuclear
cells (PBMCs) from buffy coats of healthy blood donors. CD14
+
monocytes were isolated from PBMCs by positive selection with
CD14 microbeads (Miltenyi Biotech, Bergisch Gladbach, Ger-
many). The obtained monocytes were plated at 1610
6 cells/ml
and subsequently cultured with GM-CSF (800 U/ml) and IL-4
(500 U/ml) for 5 days to differentiate into moDCs as described
previously [7]. Fresh medium containing GM-CSF and IL-4 was
added at day 2. Human myeloid DCs (mDCs) and plasmacytoid
DCs (pDCs) were obtained from freshly isolated PBMCs by
positive selection as previously described [7]. Purity of sorted DC
populations was over 99%.
Macrophages were obtained by culturing adherent PBMCs cells
for 6 days in RPMI 1640 with Glutamax (Invitrogen) and 10%
heat-inactivated FCS (Sigma-Aldrich). Human whole blood assay
was performed as described [33].
HeLa cells (ATCC, Manassas, VA) were cultured in IMDM
containing 8% fetal bovine serum (PAA) and 80 IU/ml Natrium-
penicillin (Astellas Pharma).
HIV-specific CD8 T cells were obtained from an HIV-1
seropositive long-term non-progressor [7]. First, total PBMCs were
depleted for CD4 T cells using CD4 dynabeads (Dynal) according
to the manufacturer’s protocol. The enriched CD8 T cell
population was subsequently treated as previously described [7].
Specificity was confirmed after 4 weeks of culture. Although these
CD8 T cells are not cloned from a limiting dilution, 99.8% of the
T cells express the Vb22 TCR, suggesting that these cells are
obtained from a single precursor and can be considered clonal.
Cells were restimulated every two weeks. Cells were left untreated
for at least two weeks before use in antigen presentation assay.
Primary chicken embryo fibroblast cells (CEF) and DF-1 cells (a
spontaneously immortalized chicken embryo fibroblast cell line;
ATCC, Manassas, VA) were grown in Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% fetal calf serum
(FCS).
All cells were maintained in a humidified air 5% CO2
atmosphere at 37uC except DF-1, that were maintained at 39uC.
MVA-C, a recombinant vaccinia virus Ankara expressing in the
TK locus the HIV-1 clade C Gag, Pol, Nef and Env antigens
(Fig. 1A), was constructed by homologous recombination in CEF
cells. Gag-Pol-Nef is a fusion protein composed of gag, pol and nef
ORFs from HIV-1 clone CN54, which has been modified to
enhance its immunogenicity and removed, for safety consider-
ations, undesirable domains of the HIV antigens. Gp120 Env
protein belongs to the same HIV-1 isolate (CN54). In both cases,
the codon usage was adapted to highly express human genes. The
coding sequence, gene organization, generation and some of the
immunological properties of MVA-C have been described
previously [15]. The parental and recombinant MVA-C viruses
were grown in CEF cells, purified through two 36% (w/v) sucrose
cushions, and titrated by plaque immunostaining assay in DF-1
cells as previously described [34].
HIV-1 gag expression
The expression of gag protein was measured in moDCs at
different times post-infection as previously described [7]. Cells
were infected for 1 h at MOI 1 and subsequently washed
thoroughly. From 2 to 24 h of incubation, cells were harvested
and gag expression was determined by intracellular staining with
an anti-gag specific antibody (KC57, Beckman Coulter). Cells were
analyzed on a FACSCalibur using CellQuest (BD). FACS data
were analyzed with FlowJo (Tree Star, Inc.).
Gene array analysis
Isolated mDCs and pDCs subsets were infected with MVA-C or
mock-infected for 6 h before cells were harvested for gene
expression profiling as previously described [7]. Total RNA was
purified from DC subsets using DCsRNA extraction kits
(Qiagen,USA). Quantification was performed using a spectropho-
tometer (NanoDrop Technologies, Willington, DE) and RNA
quality was assessed using the Experion
TM Automated Electro-
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amplified and labeled using the IlluminaH TotalPrep
TM RNA
Amplification kit (Illumina, Inc., San Diego, CA) as previously
described [7]. The biotinylated cRNA was then hybridized onto
Illumina Human RefSeq-8 V2 and V3 BeadChips expressing
more than 24000 probe sets spanning the whole human genome
(PBMC samples) and quantified using Illumina BeadStation
500GX scanner and Illumina BeadScan software.
Illumina probe data were exported from BeadStudio as raw
data and were screened for quality; samples failing chip visual
inspection and control examination were removed. Probeset from
the two Illumina platforms were mapped to a common probeset Id
using a mapping file provided by Illumina. A dataset containing
probeset common to both platforms was then used for subsequent
steps. Gene expression data was preprocessed.
Analysis was conducted using the R statistical language (R
Development Core Team) and various software packages from
Bioconductor, an open source project for the analysis and
comprehension of high-throughput genomic data [35]. First,
arrays displaying unusually low median intensity, low variability or
low correlation relative to the bulk of the arrays were discarded
from the rest of the analysis. Quantile normalization was applied,
followed by a log2 transformation. Bioconductor’s gene filter
package was then used to filter out genes with low expression and
insufficient variation in expression across all samples tested.
Expression values retained after this filtering process presented
intensities greater than 80 units in at least 2 samples and a log base
2 scale of at least 0.3 for the interquartile range (IQR) across all
samples tested. The LIMMA package from Bioconductor [36] was
used to fit a linear model to each probe and to perform a
(moderated) t-test on various differences of interest. The expected
proportions of false positives (FDR) were estimated from the
unadjusted p value using the Benjamini and Hochberg method
[37].
Pathway analysis
Ingenuity Pathway Analysis software (IngenuityH Systems,
www.ingenuity.com) was used to identify canonical signaling
pathways regulated by mDCs infected with MVA-C
(MDC_MVC) or pDCs infected with MVA-C (PDC_MVC).
Canonical pathway analysis identified the pathways from the
Ingenuity Pathway Analysis library of canonical pathways that
were most significant to the dataset. Illumina Probe IDs were
imported into the Ingenuity software and mapped to the Gene
Symbol from Ingenuity database. Genes that had adjusted p-
value,0.05 and |FC|.2 and associated with a canonical
pathway in Ingenuity’s Knowledge Base were used for pathway
analysis. Over-representation Fisher’s exact test was used to
calculate a p-value determining the probability that the association
between the genes in the dataset and the canonical pathway is
explained by chance alone. The pathways were ranked by -log p-
Figure 4. Signaling pathways induced upon MVA-C infection of mDCs and pDCs. Selected significant top 10 pathways and their genes
members resulting from comparing myeloid DCs infected with MVA-C (MDC_MVC) and mock-infected (MDC_Mock) groups (A) or plasmacytoid DCs
infected with MVA-C (PDC_MVC) and mock-infected (PDC_Mock) groups (B). Each row is an upregulated canonical pathway for innate immunity
(Ingenuity software); each column represents an up- (red) or down- (blue) regulated gene (p,0.05 and |FC|.2) included in 1 or more regulated
pathway(s). The over-representation test was performed using Fisher Exact Test and the significance, displayed on the right side, is achieved for
p,0.05 (-log(p).1.3).
doi:10.1371/journal.pone.0035485.g004
Figure 5. MVA-C induces maturation of human moDCs. Cells were infected with 5 pfu/cell and expression of different membrane surface
markers was determined by flow cytometry at 24 h.p.i. The shaded graphs represent cells infected with a parental WT strain. Mean fluorescence
intensity is indicated in the plots. Data are representative of at least five independent experiments.
doi:10.1371/journal.pone.0035485.g005
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PLoS ONE | www.plosone.org 9 April 2012 | Volume 7 | Issue 4 | e35485Figure 6. MVA-C induces cytokine and chemokine production in human primary macrophages. A) Human primary macrophages were
infected at 5 pfu/cell with MVA-WT or MVA-C. At 3 h.p.i., cells were collected, RNA extracted and levels of different mRNAs were defined by RT-PCR. B)
Human primary macrophages were infected (1 or 5 pfu/cell) with MVA-WT or MVA-C. Supernatants were collected at 24 h and used to quantify IL-1b,
IL-8, IFNb, MIP-1a, RANTES, IP-10 and IFNa by ELISA. Experiments were performed in triplicate samples from two human donors. Data are means and
standard deviation from one experiment representative of at least two experiments.
doi:10.1371/journal.pone.0035485.g006
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pathways significantly (p value,0.05).
Infection of DCs and flow cytometry
Freshly isolated moDCs were infected with the different viruses
at MOI 5 [7]. After 1 h of incubation, the cells were washed
extensively and plated into 24-well plates. Cells were harvested at
24 h.p.i. and fixed in 4% paraformaldehyde and subsequently
incubated with the following antibodies: a-CD86 PE-Cy5 (clone
IT2.2), a-CD80 PE-Cy5 (clone 2D10.4), a-CD11c Alexa Fluor
700 (clone 3.9) (all from eBiosciences), a-CD40 APC, a-HLA-A2
FITC and a-HLA-DR PE (all from Becton Dickinson). Cells were
analyzed on a LSRII flow cytometer using DIVA (BD). FACS data
were analyzed with FlowJo.
RNA analysis by quantitative real-time polymerase chain
reaction
Total RNA was isolated from primary human macrophages
using the RNeasy kit (Qiagen). Reverse transcription and real-time
PCR (RT-PCR) was performed with a 7500 Fast Real-Time PCR
System (Applied Biosystems, Rotkreuz, Switzerland) using the
Power SYBR Green PCR Master Mix (Applied Biosystems) and
primer pairs previously described [33]. All samples were tested in
triplicates. Gene specific expression was expressed relative to the
expression of HPRT in arbitrary units (AU). Gene specific over
HPRT ratios were validated using the house-keeping gene ACTB.
Measurement of cytokine and chemokine production
The concentrations of human IL-1b (Bender MedSystems,
Vienna, Austria), IL-8 (BD Biosciences), RANTES, IP-10, MIP-1a
(R&D), IFNa and IFNb (PBL Biomedical Laboratories, Piscat-
away, NJ) in whole blood assay and in cell culture supernatants
were measured by ELISA as previously described [33].
Antigen presentation assays
Antigen presentation to HIV-specific CD8 T cells was studied
using moDCs cross-presenting antigens from HeLa cells that were
infected at different MOIs. In addition, the cytokine production of
HIV-specific CD8 T cells was assessed as previously described [7].
For that, HeLa cells were harvested by EDTA and infected with
MVA-C or MVA-WT at different MOIs for 1 h. Cells were
extensively washed to remove residual virus. After overnight
incubation, cells were irradiated with UV-C (200 mW/cm
2)t o
ensure that no residual virus and no viable cells were present and
thus exclude direct presentation. Apoptotic virus-infected HeLa
cells were harvested and added to moDCs at a 2:1 ratio. After 6 h
incubation, HIV- or VACV-specific CD8 T cells were added (at
approximately 5 T cells : 1 DC ratio) followed by overnight culture
at 37uC/5%CO2. Brefeldin A (10 mg/ml, Sigma-Aldrich) was
added to retain cytokines within the T cells allowing the detection
of multiple cytokines. After 18 hours, intracellular cytokine
staining (ICS) was performed as described. Cells were fixed and
permeabilized using Cytofix/Cytoperm
TM Fixation/Permeabili-
zation Solution Kit (BD). Cells were then incubated with a-TNF
PE-Cy7 (clone MAb11, eBiosciences), a-IFN-c FITC, a-IL-2
APC, a-MIP-1b PE (all three from BD) and a-CD8 PerCP (Dako)
antibodies. After washing, cells were analyzed on a LSRII flow
cytometer using DIVA (BD). FACS data were analyzed with
FlowJo. Net accumulation is the percentage of live CD8
+ cells
expressing a specific cytokine upon stimulation with moDCs
loaded with apoptotic virus-infected HeLa cells.
Ex vivo proliferation assay
Overnight-rested cryopreserved PBMCs from an HIV-1
seropositive long-term non-progressor were washed twice, resus-
pended at 1610
6 cells/ml in PBS and incubated for 79 at 37uC
with 0.25 mM 5,6-carboxyfluorescein succinimidyl ester (CFSE,
Molecular Probes, USA) as described [38]. Then, the reaction was
quenched with one volume of FCS and cells were washed twice.
Cells were then cultured (1610
6 cells in 1 ml of complete medium)
in the presence of MVA-WT or MVA-C vectors at different
MOIs, medium alone (negative control) or Staphylococcal
enterotoxin serotype B (SEB, 40 ng/ml, positive control). At day
6, cells were harvested, stained for dead cells using the Aqua
LIVE/DEAD stain kit (Invitrogen) and then with anti-CD3, -CD4
and -CD8 antibodies. After fixation, cells were acquired on an
LSRII flow cytometer using DIVA (BD). FACS data were
Figure 7. MVA-C infection induces antigen cross-presentation
to CD8 T cells and T cell proliferation. A) Human moDCs were
incubated with apoptotic infected-HeLa cells before a CD8 T cell clone
was added. After overnight incubation, cells were harvested and among
the lymphocyte population, CD8 cells were gated and analyzed for IFN-
c, TNF-a, IL-2 and MIP-1b production. Cytokine production by HIV-
specific CD8 T cells was determined. Percentages of CD8 T cells
producing any cytokine are indicated at the various virus multiplicities.
B) MVA-C and parental MVA-WT were evaluated in vitro using
cryopreserved PBMCs from an HIV-1-infected subject. Cell proliferation
using the CFSE dilution assay was measured 6 days after stimulation. At
the end of the stimulation period, cells were stained for CD3, CD4, CD8
and a viability marker and analyzed by flow cytometry. Mean values and
standard deviation of at least three experiments are shown in panels A
and B.
doi:10.1371/journal.pone.0035485.g007
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events ranged between 1610
5 and 5610
5 in all experiments.
Mice immunization schedule
Balb/c mice (6–8 weeks old) were purchased from Harlan.
DNA prime/Poxvirus boost immunization protocol was per-
formed as previously described [15]. Groups of animals (n=4)
received 100 mg of DNA-C (50 mg of pcDNA-CN54gp120 +50 mg
of pcDNA-CN54GPN) by intramuscular route (i.m.) and two weeks
later received an intraperitoneal (i.p.) inoculation of 1610
7 pfu of
the corresponding virus. Animals primed with sham DNA (DNA-
w) and boosted with the non-recombinant MVA-WT were used as
control group. At 53 days after the last immunization, animals
were sacrificed and spleens processed for Intracellular Cytokine
Staining (ICS) assays to measure the HIV-1-specific memory
immune responses. Two independent experiments have been
performed for the different groups.
Intracellular cytokine staining assay (ICS)
The magnitude, polyfunctionality and phenotype of the HIV-1
specific T cell responses were analyzed by ICS. After an overnight
rest, 5610
6 splenocytes (depleted of red blood cells) were
stimulated during 6 h in complete RPMI 1640 media containing
1 ml/ml Golgiplug (BD Biosciences) and 5 mg/ml of different HIV-
1 peptide pools that have being previously described [15]. At the
end of the stimulation period, cells were washed, stained for the
surface markers, permeabilized (Cytofix/Cytoperm kit; BD
Biosciences) and stained intracellularly using the appropriate
fluorochromes. For functional analyses the following fluoro-
chromes-conjugated antibodies were used: CD3-FITC, CD4-
Alexa 700, CD8-PerCP or 2V500, IL-2-PE or -APC, IFN-c-APC
or -PECy7 and TNF-a-PECy7 or 2PE. In addition, for
phenotypic analyses the following antibodies were used: CD62L-
FITC and CD44-SPRD. Dead cells were excluded using the violet
LIVE/DEAD stain kit (Invitrogen). All antibodies were from BD
Biosciences. Cells were acquired using an LSRII flow cytometer
(BD Immunocytometry Systems). Analyses of the data were
performed using the FlowJo software version 8.5.3 (Tree Star,
Ashland, OR). The number of lymphocyte-gated events ranged
between 1610
5 and 1610
6. After gating, Boolean combinations of
single functional gates were then created using FlowJo software to
determine the frequency of each response based on all possible
combinations of cytokine expression or all possible combinations
of differentiation marker expression. Background responses
detected in negative control samples were subtracted from those
detected in stimulated samples for every specific functional
combination.
Antibody measurements by ELISA
Binding antibodies to Env protein in serum were assessed by
ELISA as previously described [15]. Serum from naı ¨ve and
immunized mice were serially two-fold diluted in duplicate and
reacted against 2 mg/ml of the recombinant 97CN54 gp140
purified protein (clade C) (kindly provided by Simon A. Jeffs,
Imperial College London, UK). The antibody titer of Env-specific
IgG was defined as the last dilution of serum that gives 3 times the
mean OD450 value of the naı ¨ve control. For analysis of IgG
subtypes, serum from naı ¨ve and immunized mice were reacted at
Figure 8. Long-lived memory immune response to HIV antigens elicited by MVA-C. A) Magnitude of vaccine-specific CD4
+ and CD8
+ T
cells. The HIV-1-specific CD4 and CD8 T cells were measured 53 days after the last immunization by ICS assay following stimulation with the different
HIV-1 peptide pools. The values represent the sum of the percentages of T cells secreting IFN-c and/or TNF-a and/or IL-2 against Env+Gag+GPN
peptide pools. All data are background subtracted. B) Functional profile of memory HIV-1-specific CD4 and CD8 T cell responses. All the possible
combinations of the responses are shown on the x axis, whereas the percentage of the functionally distinct cell populations within the total CD4 or
CD8 T cell populations are shown on the y axis. Responses are grouped and colour-coded on the basis of the number of functions. The non-specific
responses obtained in the control group DNA-W/MVA-WT were subtracted in all populations. C) Phenotypic profile of memory HIV-1-specific CD4 or
CD8 T cells. Representative FACS plots showing the percentage of Env-specific CD4 or CD8 T cells with central memory (TCM, CD44
highCD62L
+)o r
effector memory (TEM, CD44
highCD62L
2) phenotype. * p,0.05; ** p,0.005. p-values indicate significantly higher responses compared to DNA-W/
MVA-WT immunization group.
doi:10.1371/journal.pone.0035485.g008
Figure 9. Humoral immune responses elicited by MVA-C
against HIV-1 gp140 protein. Levels of Env-specific IgG binding
antibodies (A) or IgG subtypes (B) were measured in serum from naı ¨ve
and immunized mice at 53 days after the boost. The values represent
the mean antibodies titer for each group. ** p,0.005.
doi:10.1371/journal.pone.0035485.g009
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97CN54 gp140.
Statistical analyses
For antigen presentation and ex-vivo proliferation assays the p-
values were calculated using Mann-Whitney U test using SPSS
16.0 (SPSS Inc). For RNA levels and cytokine production the
comparisons among treatment groups were performed by two-
tailed paired Student’s t-test. Previously, a normality test was used
to verify that samples assumed normal distribution. p-values less
than 0.05 were considered to indicate statistical significance.
For the statistical analysis of ICS data we used a novel approach
that corrects measurements for the medium response (RPMI) and
at the same time allows the calculation of confidence intervals and
p-values of hypothesis tests [39,40]. The background for the
different cytokines in the unstimulated controls never exceeded
0.05%. The data analysis program, Simplified Presentation of
Incredibly Complex Evaluations (SPICE, version 4.1.5, Mario
Roederer, Vaccine Research Center, NIAID, NIH), was used to
analyze and generate graphical representations of T cell responses
detected by polychromatic flow cytometry. All values used for
analyzing proportionate representation of responses are back-
ground-subtracted.
Supporting Information
Figure S1 Multidimensional scaling plot illustrating
distinct gene expression profile of the mDCs and pDCs
infected with MVA-C (MDC_MVC and PDC_MVC) and
mock-infected groups (MDC_Mock and PDC_Mock).
8552 probes that pass the filtering step were used for this plot.
(TIF)
Table S1 List of differentially expressed (up- or down-regulated)
genes between myeloid DCs infected with MVA-C (MDC_MVC)
and mock-infected (MDC_Mock) groups. The threshold of
differential expression is set at FDR 5%, with FC.1.3.
(XLS)
Table S2 List of differentially expressed (up- or down-regulated)
genes between plasmacytoid DCs infected with MVA-C
(PDC_MVC) and mock-infected (PDC_Mock) groups. The
threshold of differential expression is set at FDR 5%, with
FC.1.3.
(XLS)
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